Startup Funding Tracker
Home›People›Evan Melrose
EM

Evan Melrose

Director at Elucid; CEO of Elevage Medical Technologies as of March 2026

DirectorPublic companyRoles at 2 startups
LinkedInBio on spindletopcapital.com
Updated Nov 9, 2026·Latest SEC filing Oct 27, 2026·Suggest an edit

About Evan Melrose

Evan Melrose is a physician and healthcare investor. In May 2023, Patient Square Capital named him CEO of Elevage Medical Technologies, a new platform that invests in medical device companies. He joined the board of Elucid, a Boston company that makes AI software to read plaque in heart and neck arteries on CT scans, in November 2023. In March 2026 he joined the board of Imperative Care, a medical device company that treats stroke and other vascular disease.

Melrose was founding managing director of Spindletop Capital, an Austin healthcare growth investor, from 2011. Before that he was founding managing director of PTV Sciences, an Austin venture capital firm, and a director at Burrill & Company. He became chairman of QSpex Technologies in 2014. His other board seats have included IntersectENT, Bioventus, Castle Biosciences, Sanova Dermatology, Asuragen and Inhibitex. He has held faculty posts at Baylor College of Medicine, UC San Francisco and the University of Pennsylvania. He holds a BA from Penn, an MD from Indiana University School of Medicine and an MBA from the Wharton School.

Experience

This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name Evan Melrose in the role, so the role may have started earlier or lasted longer.

Elucid Bioimaging Inc.
Director
2023 – 2026 · Boston, MA
Elucid makes AI software that measures plaque in heart and neck arteries from CT scans to help doctors choose treatment.
Imperative Care, Inc.
Director
2026 · Campbell, CA
Makes devices that help clinicians remove blood clots from stroke and vascular patients.
Elevage Medical Technologies
Chief Executive Officer
From 2023
Spindletop Health Acquisition Corp.
Chief Executive Officer and Chief Financial Officer
Director
2021 · Public company (SCHAU)
Bioventus Inc.
10% owner
Board member (From 2012)
2012 – 2021 · Public company (BVS)
Spindletop Pain Holdings
Board member
From 2018
Sanova Dermatology
Board member
From 2017
QSpex Technologies
Chairman
From 2014
Spindletop Capital
Founding Managing Director
From 2011
Insite Vision Inc.
Director and 10% owner
2006 – 2010 · Public company (INSV)
Bioform Medical Inc.
Director and 10% owner
2007 · Public company (BFRM)
PTV Sciences
Founding Managing Director
Burrill & Company
Director
Baylor College of Medicine
University of California, San Francisco
University of Pennsylvania
IntersectENT
Board member
Castle Biosciences
Board member
Asuragen
Board member
BioSET
Board member
BioMimetic Therapeutics
Board member
Inhibitex
Board member

Key Colleagues at Startups

The people Evan Melrose works with at each company, as listed on that company's latest Form D.

Elucid Bioimaging Inc. · Form D/A, Oct 27, 2026
Blake Richards
Blake Richards
Chief Operating Officer
Scott Huennekens
Scott Huennekens
Chairman of the Board
ML
Michael Lesh
Director
RK
SF
Kelly Huang
Kelly Huang
President and Chief Executive Officer, director
RP
Rajesh Panda
Director
Imperative Care, Inc. · Form D/A, Jul 10, 2026
Richard Leparmentier
Richard Leparmentier
Chief Technology Officer
Kevin Reilly
Kevin Reilly
Director
FK
Farhad Khosravi
Executive officer and director
JM
John Martin
Executive officer
AH
Andrew Hack
Director
SS
Stacy Seng
Director
SE
Scott Elliott
Chief Legal Officer
CR
Carole Roth
Chief People Officer
CA
Charles Alpuche
Executive officer
HS
TB
Tyler Binney
Director
HJ
Todd Van Horn
Todd Van Horn
Chief Financial Officer
JH
John Hamre
Director
DJ
SP
Shacey Petrovic
Vice Chair

Evan Melrose in the News

Sources

  1. SECElucid Bioimaging Inc. Form D/A, filed Oct 27, 2026
  2. SECImperative Care, Inc. Form D/A, filed Jul 10, 2026
  3. SECForms 3, 4 and 5 filed by Evan Melrose (SEC filer 1373063)
  4. PressPatient Square Capital release on forming Elevage Medical Technologies (May 1, 2023)
  5. PressElucid Series C release naming him to its board (November 9, 2023)
  6. PressImperative Care financing release naming him to its board (March 17, 2026)
  7. Company siteBio on spindletophealth.com
  8. PressQSpex Technologies Series E release (January 2014, copy on BioSpace)
  9. Company siteTeam page on elevagemedical.com